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Abstract:
Background 
Cerebral small vessel disease (SVD) is a major cause of dementia and 
st oke, visible on brain MRI. Recent data suggests SVD lesions may be 
dynamic, damage extends into normal-appearing brain, and 
microvascular dysfunctions include abnormal blood-brain barrier leakage, 
vasoreactivity and pulsatility, but much remains unknown regarding 
underlying pathophysiology, symptoms, clinical features and risk factors 
of SVD. 
Study Methods/Design 
The Mild Stroke Study 3 (MSS-3) is a prospective observational cohort 
study to identify risk factors for and clinical implications of SVD 
progression and regression among up to 300 adults with non-disabling 
stroke. We perform detailed serial clinical, cognitive, lifestyle, 
physiological, retinal and brain MRI assessments over one year; we 
assess cerebrovascular reactivity, blood flow, pulsatility, blood-brain 
barrier leakage on MRI at baseline; we follow up to four years by post 
and phone. The study is registered ISRCTN 12113543. 
Discussion 
Factors which influence direction and rate of change of SVD lesions are 
poorly understood. We investigate the role of small vessel dysfunction 
using advanced serial neuroimaging in a deeply phenotyped cohort to 
increase understanding of the natural history of SVD, identify those at 
highest risk of early disease progression or regression and uncover novel 
targets for SVD prevention and therapy. 
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ABSTRACT 
Background
Cerebral small vessel disease (SVD) is a major cause of dementia and stroke, visible on brain 
MRI. Recent data suggests SVD lesions may be dynamic, damage extends into normal-
appearing brain, and microvascular dysfunctions include abnormal blood-brain barrier 
leakage, vasoreactivity and pulsatility, but much remains unknown regarding underlying 
pathophysiology, symptoms, clinical features and risk factors of SVD.
Study Methods/Design
The Mild Stroke Study 3 (MSS-3) is a prospective observational cohort study to identify risk 
factors for and clinical implications of SVD progression and regression among up to 300 
adults with non-disabling stroke. We perform detailed serial clinical, cognitive, lifestyle, 
physiological, retinal and brain MRI assessments (structural, white and grey matter 
integrity) over one year; we assess cerebrovascular reactivity, blood flow, pulsatility, blood-
brain barrier leakage on MRI at baseline; we follow up to four years by post and phone. The 
study is registered ISRCTN 12113543.
Discussion
Factors which influence direction and rate of change of SVD lesions are poorly understood. 
We investigate the role of small vessel dysfunction using advanced serial neuroimaging in a 
deeply phenotyped cohort to increase understanding of the natural history of SVD, identify 
those at highest risk of early disease progression or regression and uncover novel targets for 
SVD prevention and therapy.
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Background
Cerebral small vessel disease (SVD) describes diffuse disease processes affecting the 
perforating cerebral arterioles, capillaries, venules and consequent damage to the white and 
deep grey matter.(1) This damage is visible on brain MRI as white matter hyperintensities 
(WMH), lacunar recent small subcortical infarcts, perivascular spaces, focal cortical 
thinningbrain atrophy, and cerebral microbleeds.(2) 
SVD causes 20% of ischaemic strokes and almost half of all dementias,(3, 4) contributing to 
both vascular and Alzheimer’s dementia subtypes,(5) its presence more than doubling 
future risk of stroke, dementia and functional impairment.(6)  
Recent advances in neuroimaging have uncovered candidate mechanisms for underlying 
pathophysiological processes. Furthermore, SVD appears to be more dynamic and global 
than previously thought, since recent studies show: (a) WMH can regress as well as 
progress;(7-10) (b) SVD is associated with cerebrovascular dysfunction including diffuse 
blood-brain barrier failure;(11) (c) with some evidence for other vascular dysfunctions 
including reduced cerebrovascular reactivity (CVR) and increased intracranial pulsatility;(12-
14) and d) acute, apparently ‘silent’, lesions on Diffusion Weighted Imaging (DWI) may be 
more frequent than previously thought.(15-17)
Most SVD lesions are thought to develop ‘silently’. However, some studies suggest that SVD 
lesions are associated with subjective cognitive complaints,(18) gait disturbance,(19) mood 
disorders and apathy.(20) Moreover, subtle symptoms have been associated with acute DWI 
lesions in a few small cross-sectional studies in non-stroke populations (n=6/649; 
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n=10/30),(21, 22) while apparently ‘silent’ acute DWI lesions have been noted in up to 25% 
following recent stroke, mostly in small studies (e.g. n<105) that sought typical stroke 
symptoms.(16, 23) Thus, knowledge of the extent of clinical correlates of SVD lesions, in 
particular, any ‘red flag’ symptoms or signs that might highlight lesion worsening, remains 
limited and may be being clinically overlooked. 
SVD is commonly attributed to traditional vascular risk factors, particularly hypertension, 
but also smoking and diabetes, yet these factors only account for 2% of WMH variance.(24) 
Less is known about potential contributors such as diet, lifestyle and premorbid factors.(25) 
Extending the search beyond an individual’s current clinical status to early and mid-life 
stages is an important target for SVD research.(26) Understanding whether combined risk 
factors have a synergistic effect on an individual’s risk of developing SVD, as well as 
improved recognition of symptoms, would provide better recognition of persons at risk of 
SVD development or progression, providing insight on whether multimodal approaches to 
prevention and treatment should be taken. 
Few studies have comprehensively assessed SVD lesion progression, symptomatology and 
wide-ranging risk factors. Hence we describe the protocol for a detailed study to assess the 
role of cerebrovascular dysfunctions in combination, symptoms, risk factors including diet, 
sleep, and early life factors, on longitudinal SVD lesion change in patients presenting with 
stroke-related SVD.
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Methods
Study design
The Mild Stroke Study 3 (MSS-3: ISRCTN 12113543) is a detailed prospective observational 
cohort study with clinical and imaging follow-up which aims to recruit up to 300 
participants. In addition to a scan at initial stroke diagnosis, the patients undergo a minimum 
of three study scans over a year; in addition, those with lacunar stroke or moderate to severe 
white matter hyperintensities are invited for a further one or two scans between baseline and 
six months. The baseline assessment occurs within a maximum of 3 months of index stroke 
(Table 1). We invite most participants to attend an interim visit 2-3 months later. All 
participants return 6 and 12 months respectively after the baseline assessment. Annually 
thereafter up to four years, we will invite participants to continue annual postal or phone 
follow-up with another MRI at 3 years. The follow-up questionnaire includes recurrent 
vascular events, cognition and functional status. MSS-3 benefits from systems established 
during the MSS-1 and MSS-2 studies(27, 28) and commenced in August 2018.
Study population
Adults >18 years old with mild ischaemic stroke with a modified Rankin Scale (mRS) ≤2 at 
recruitment presenting to Edinburgh/Lothian stroke services.
Eligibility criteria
We define stroke as previously(27, 28): clinical lacunar stroke syndrome (50%) and control 
participants with non-lacunar ischaemic stroke syndromes (50%) i.e. partial anterior 
circulation syndrome or posterior circulation syndrome, with recent infarct visible on 
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diagnostic MRI or CT scan compatible with the clinical syndrome, or if no visible infarct, no 
other lesion explaining the stroke symptoms. Participants with non-lacunar stroke form 
controls, since they have similar vascular risk factors and follow similar secondary 
prevention, accounting for medication effects on vessel function.
We exclude participants with MRI contraindications, major neurological conditions, severe 
cardiac and respiratory disease. All participants give written informed consent. The study 
was granted ethical approval by Southeast Scotland Regional Ethics Committee (reference 
18/SS/0044).
Diagnosis
An expert panel of stroke physicians and neuroradiologists reach final stroke diagnosis by 
consensus following review of presenting symptoms and signs including motor or sensory 
deficit, hemianopia, visuospatial disorder, ataxia, dysphasia, dysarthria, cerebellar or 
brainstem symptoms, supplemented by diagnostic brain MRI or CT and other relevant 
investigations, as previously.(27, 28) An experienced neuroradiologist (J.M.W.) assesses all 
scans for acute ischaemic lesions including recent small subcortical infarcts, prior infarcts or 
haemorrhages, WMH, lacunes, PVS, microbleeds, siderosis, atrophy, using standardized 
validated scales.(2, 28) 
Table 1: Study assessments
Activity/assessment Pre-visit V1ᵃ baselineᵃ V2ᵇ: 2-3 months* V3ᶜ: 6 months V4ᵈ: 12 months
Eligibility X
Diagnostic MRI/CT X
Consent X
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Routine blood tests X
Electrocardiogram X
Carotid doppler ultrasound X
Symptom assessment X X X X
Cognitive tests X X X X
MRI X X X X
Retinal imaging X X X X
Blood pressure X X X X
Recurrent vascular events X X X X
NIHSS X X X X
Modified Rankin Scale X X X
Medical history/vascular risk factors X X X
Demographic/socioeconomic factors X
Diet questionnaire X
Sleep questionnaire X
Mood/fatigue questionnaires X 
Blood/urine collection X
24-hour blood pressure monitoring X
Premorbid IQ (education, National 
Adult Reading Test)
X
Informant questionnaire: IQCODE, 
NPI-Q, AES-I
X X 
Pulse wave measures X
9-hole peg test X X
Timed Up+Go X X 
Stroke Impact Scale X X
ᵃVisit 1: baseline visit within 3 months of index stroke +/- 1 week
ᵇVisit 2: 2-3 months+/- 1 week
ᶜVisit 3: 6 months +/- 2weeks
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ᵈVisit 4: 12 months +/- 3weeks
MRI=Magnetic Resonance Imaging, NIHSS=National Institute of Health Stroke Scale, 
IQCODE=Informant Questionnaire for Cognitive Decline in the Elderly, NPI-Q=Neuropsychiatric 
Inventory Questionnaire, AES-I=Apathy Evaluation Scale-Informant
Vascular risk factors, past medical history, medications, incident vascular events
Each participant provides a medical history of diagnoses confirmed by a physician, 
supplemented by hospital medical records and general practitioner correspondence, 
following standard definitions, including diabetes mellitus, hypertension, 
hypercholesterolaemia, previous stroke or TIA, peripheral vascular disease, atrial fibrillation, 
ischaemic heart disease, valvular defects, heart failure and physician-diagnosed anxiety, 
depression or delirium. We record current medications, cross-checking with electronic 
medical records. At follow-up we record recurrent stroke, TIA and cardiac events.
Subjective symptoms
We use a structured questionnaire to ask open-ended questions about subjective symptoms 
experienced prior to, at the time of, and since index stroke diagnosis (see Supplementary 
Appendix 1). Participants also answer questions based on previous clinico-radiological 
studies regarding symptoms within the past month including subjective memory concerns, 
confusional episodes, unsteadiness, falls, dizziness and headaches.(29) 
Participants self-administer the Fatigue Severity Scale,(30) Generalized Anxiety Disorder-
7,(31) the Center for Epidemiologic Studies-Depression Scale,(32) and an adapted Pittsburgh 
Sleep Quality Index.(33)
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Informant-reported symptoms
A nominated close friend or relative completes the following prior to the baseline visit: 
Neuropsychiatric Inventory Questionnaire,(34) behavioural changes since stroke,(35) Apathy 
Evaluation Scale, Informant version(36) and the Informant Questionnaire for Cognitive 
Decline in the Elderly,(37) repeated at 12 months.
Family, lifestyle, social, early life factors
We record stroke or dementia family history including age at diagnosis, alcohol 
consumption and smoking status including quantity and duration. Participants self-
administer the EPIC-Norfolk Food Frequency Questionnaire, a comprehensive dietary 
overview including salt intake.(38, 39)
To assess early life socioeconomic status, we record childhood postal address, number of 
individuals, rooms and toilets in the property and parental occupations. We note ethnicity, 
educational duration and attainment,(40) occupation, current postcode and retirement age.
 
Physical examination
We record presenting and current neurological deficits and stroke severity (NIHSS), blood 
pressure 3 times, gait (Timed Up and Go), manual dexterity (9-Hole Peg Test), height and 
weight. 
Cognitive assessment
Participants complete the comprehensive 30-minute neuropsychological test protocol based 
on the National Institute of Neurological Disorders and Stroke–Canadian Stroke Network 
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(NINDS-CSN) Vascular Cognitive Impairment Harmonization Standards. This battery spans 
multiple cognitive domains and includes the Montreal Cognitive Assessment (MoCA), 
Hopkins Verbal Learning Test-revised, Controlled Oral Word Association Test, Animal 
Naming, Letter Digit Coding, and Trailmaking Tests A+B.
We estimate peak adult intelligence using the National Adult Reading Test.(40)
Participants repeat MoCA and Trailmaking Tests A+B at each visit. We use three different 
MoCA versions, randomly assigning a test sequence to each participant to minimize learning 
effects on serial test performance. 
Functional recovery
We administer the modified Rankin Scale(41) at baseline, 6 and 12 months and the Stroke 
Impact Scale(42) at 6 and 12 months.
Magnetic Resonance Imaging
We scan all participants at diagnosis at 1.5T (General Electric Signa HDxt) or 3T (Siemens 
Prisma) MRI or CT with core structural brain MRI sequences at each visit: 3D T1w, T2w, Fluid 
Attenuated Inversion Recovery (FLAIR), Susceptibility-weighted (SWI/SWAN/GRE), and 
single- or multi-shell diffusion imaging (dMRI). Subsequent full cerebrovascular assessment 
and all follow-up imaging is at 3T.
At 1-3 months post-stroke, participants undergo 3T MRI to measure blood-brain barrier 
(BBB) integrity, CVR, cerebral blood flow (CBF) and intracranial vascular and CSF pulsatility 
(protocol in Supplementary Appendix 2). We assess BBB integrity using dynamic contrast-
enhanced (DCE-) MRI and gadolinium-based contrast agent (gadobutrol) injection,(11, 43) 
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unless eGFR<30ml/min. We assess CVR using a Blood Oxygenation Level Dependent (BOLD) 
MRI sequence, during which participants inhale air with intermittent added CO2 (12-minute 
paradigm alternating 2 minutes air and 3 minutes 6% CO2) through a tight-fitting facemask, 
described previously.(13, 44) Arterial, venous and CSF pulsatility are measured using phase 
contrast MRI sequences.(14, 44) We measure CBF using major arterial phase contrast flow 
measures obtained during pulsatility measurements (and arterial spin labelling where 
feasible). 
We process MRI computationally using well-validated methods to assess intracranial 
volume, brain, CSF, normal-appearing white and grey matter, WMH volumes, index and 
prior stroke lesion volumes, lacunes, microbleeds and perivascular space metrics.(45, 46) 
We visually quantify index and prior stroke lesions (location, type), WMH (baseline, change), 
lacunes (number, location), perivascular spaces, microbleeds, siderosis, superficial and deep 
brain volume loss, according to STRIVE criteria using validated scales.(2, 47-51)  See 
Supplementary Appendix 2 for image processing methods description including advanced 
neuroimaging data.
Retinal imaging
We assess vision (Logmar cabinet, Sussex Vision) and use Spectralis OCT2® with Optical 
Coherence Tomography Angiography (OCTA)(Heidelberg Engineering) at each visit, imaging 
retinal vessels, retinopathy, nerve fibre layer thickness, choroid OCTA, intra-retinal and sub-
retinal fluid. We computationally process retinal and arteriolar widths, branching patterns, 
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complexity,(52) nerve fibre layer thickness and microvessels on OCTA using well-validated 
tools.(53) See Supplementary Appendix 2 for processing details. 
Systemic vascular measures
We record BP at three standard points during the baseline visit and measure arterial 
velocities through pulse wave velocity and pulse wave analysis using a tonometric device 
(SphygmoCor®, AtCor Medical/Vicorder, Skidmore Medical) held over the carotid and 
radial pulses while supine. We provide a 24-hour ambulatory BP monitoring device 
(SpaceLabs Medical) to most and encourage all to submit self-monitored blood pressure 
recordings. We repeat BP measurements at all study visits.
Biochemical, haematological, cardiovascular, imaging investigations
We document routinely collected index stroke investigation results including serum 
haematology and biochemistry, electrocardiogram, echocardiography and carotid Doppler 
ultrasound. We collect 18ml venous blood at baseline for inflammatory and endothelial 
function markers. We store 20ml urine for inflammatory marker analysis and 5ml for 
albumin-to-creatinine ratio.
Endpoints 
The primary endpoint is the proportion of SVD lesions that regress, progress or appear de 
novo in the year after stroke. The secondary endpoints are: (a) blood-brain barrier (BBB) 
integrity; (b) cerebrovascular reactivity (c) intracranial vascular/CSF pulsatility; (d) WMH, PVS, 
lacunes and microbleeds; (e) white matter structural integrity measured with diffusion tensor 
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and T1 parameters; and (f) incidence of reported symptoms including neuropsychiatric and 
cognitive symptoms, recurrent stroke, transient ischaemic attacks and cardiac events.
Statistical analysis
Sample size calculation
In a previous study with one year of longitudinal imaging follow-up at this centre, 10.6% of 
participants had a de novo lesion on MRI at follow-up.(28) In the same study, 65% had a mean 
5.5ml WMH volume increase and 35% had a mean 6.6ml decrease.(54) A sample of 250 
participants would be required to detect WMH change in the year after stroke, with 
significance 0.05 and power 0.90 in univariate analysis. We aim to recruit up to total 300 
participants which allows for loss to follow-up.(54)
Proposed analyses
In our primary analyses, we will use linear mixed effects models adjusted for age, vascular risk 
factors and baseline SVD burden to estimate the effect of cerebrovascular structure/function 
on SVD lesion progression and regression.  
Secondarily, we will use similar models and other approaches (e.g. stratifying by low vs. high 
SVD burden, stroke subtype) to quantify associations of the following factors with lesion 
change: cognitive test scores and incident cognitive impairment; functional status; life course 
factors; lifestyle factors; blood pressure; systemically measured vascular stiffness; retinal 
measures; and inflammatory and endothelial function markers.
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Discussion
The Mild Stroke Study 3 is a detailed prospective observational study which will advance our 
knowledge of how detailed measures of small vessel dysfunction and changing lesions relate 
to comprehensive symptom, cognitive, retinal, early life and lifestyle factors, whether some 
individuals are more vulnerable than others to the effects of small vessel dysfunction and 
whether a single candidate measure could best differentiate abnormal from normal-
appearing brain tissue by stage and severity of SVD.
This study is novel in its concurrent use of advanced neuroimaging techniques to measure 
CVR, BBB leakage, CBF and vascular/CSF pulsatility; the first time these measures have been 
performed contemporaneously, alongside an unprecedented comprehensive assessment of 
symptoms and signs as they relate to these measures and lesion changes across multiple 
time-points. We build on previous studies,(8, 55) establishing a well-phenotyped profile of 
the dynamic natural history of SVD, capturing this rich dataset in the subacute post-stroke 
phase, monitoring the vulnerable brain at risk for early disease accumulation.(16, 56) Our 
systematic approach is a template for application to future research studies, designed to 
optimally assess rates of disease progression and regression, translatable to other SVD 
presentations including mild cognitive impairment.
This study will fill an existing gap of longitudinal imaging studies evaluating symptoms such 
as apathy, fatigue, anxiety, delirium, sleep disturbance, and emotional lability, contributing 
to the detection of preclinical SVD states. We will identify ‘red flags’ to the presence and 
progression of SVD so that we may intercept disease earlier, even before it develops, rather 
than in patients presenting with overt brain dysfunction e.g. stroke, dementia. We will gain 
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insight into novel preventative and therapeutic targets by uncovering the nature of and 
factors associated with lesion regression. This study will deepen our understanding of SVD, 
essential to future prevention and treatment of stroke and vascular dementia.
To date we have recruited 105 participants. The baseline visit lasts 6.5 hours and most are 
willing to attend three further visits, each lasting two hours, with positive participant 
feedback, demonstrating the feasibility of applying this design at other centres.
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Mild Stroke Study 3: Initial Data Collection Form MSS-3 Study Number_________
Version 2.0 Page 1 of 4 28th August 2018
Title: Studies of small vessel diseases: the Mild Stroke Study 3 (MSS-3). The longitudinal 
study of cerebral small vessel diseases following mild ischaemic stroke: rationale and 
design.
Supplement 1: Symptom questionnaire
OTHER SYMPTOMS 
Q45 (a) Other than the symptoms that first brought you to medical attention with your 
stroke, did you have any other symptoms in the month prior to the stroke?   
Yes / No / Unknown
If “no”, go to Q46
 (b) If yes, please describe:
 
Symptom 1_______________________________________________________________
Symptom 2(optional) 
________________________________________________________________________
Symptom 3(optional) 
________________________________________________________________________
(c) Categorise domain of symptoms under the following: 
Symptom 1 Gait / Low mood / Anxiety / Cognition / Apathy / Sleep and fatigue / Urinary / 
Sensory / Motor / Visual / Speech / Other 
Symptom 2 (optional): Gait / Low mood / Anxiety / Cognition / Apathy / Sleep and fatigue / 
Urinary / Sensory / Motor / Visual / Speech / Other 
Symptom 3 (optional): Gait / Low mood / Anxiety / Cognition / Apathy / Sleep and fatigue / 
Urinary / Sensory / Motor / Visual / Speech / Other 
(d) Categorise characteristics of symptoms under the following:
Symptom 1: 
Sudden onset / gradual onset /unknown
Duration <24hours / duration >24hours /unknown
Focal / non-focal /unknown
Resolved / ongoing /unknown
Symptom 2 (optional):
Sudden onset / gradual onset /unknown  
Duration <24hours / duration >24hours /unknown
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Focal / non-focal /unknown
Resolved / Ongoing /unknown
Symptom 3:
Sudden onset / gradual onset  /unknown
Duration <24hours / duration >24hours /unknown
Focal / non-focal /unknown
Resolved / Ongoing /unknown
Q 46 (a) Other than the symptoms that first brought you to medical attention, have you had 
any other symptoms since the stroke?  
Yes / No / Unknown
If “no”, go to Q47
(b) If yes, please describe: 
Symptom 1_______________________________________________________________
Symptom 2(optional) 
________________________________________________________________________
_
Symptom 3(optional) 
________________________________________________________________________
(c) Categorise domain of symptoms under the following: 
Symptom 1 Gait / Low mood / Anxiety / Cognition / Apathy / Sleep and fatigue / Urinary / 
Sensory / Motor / Visual / Speech / Other 
Symptom 2 (optional): Gait / Low mood / Anxiety / Cognition / Apathy / Sleep and fatigue / 
Urinary / Sensory / Motor / Visual / Speech / Other 
Symptom 3 (optional): Gait / Low mood / Anxiety / Cognition / Apathy / Sleep and fatigue / 
Urinary / Sensory / Motor / Visual / Speech / Other 
(d) Categorise characteristics of symptoms under the following:
Symptom 1: 
Sudden onset / gradual onset /unknown
Duration <24hours / duration >24hours /unknown
Focal / non-focal /unknown
Resolved / ongoing /unknown
Symptom 2 (optional):
Sudden onset / gradual onset /unknown  
Duration <24hours / duration >24hours /unknown
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Focal / non-focal /unknown
Resolved / Ongoing /unknown
Symptom 3:
Sudden onset / gradual onset  /unknown
Duration <24hours / duration >24hours /unknown
Focal / non-focal /unknown
Resolved / Ongoing /unknown
Q 47 Have you had any previous episodes of delirium? 
(Select “No” if the following criteria are met: diagnosis is not recorded anywhere on TRAK 
correspondence or ECS and the patient has never been informed by a healthcare 
professional that they have got the diagnosis that is listed)
Yes /
No /
Unknown
Q 48 Do you have any concerns about your memory?
Yes /
No /
Unknown
Q49 Have you experienced a feeling of “brain fog” or lack of clarity in thinking during the 
past month?
Yes /
No /
Unknown
Q50 Have you experienced any episodes of confusion or felt confused during the past 
month?
Yes /
No  / 
Unknown
Q51 Have you felt unsteady on your feet during the past month?
Yes /
No /
Unknown
Q 52 Have you experienced any light-headedness, dizziness, vertigo, or any combination 
of the above during the past month 
(a) 
Yes /
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No /
Unknown
(b) If yes, did you experience: 
1- light-headedness 
2- dizziness 
3- vertigo 
4- a combination of any of the above
Q53 Have you had any falls in the past month? (Note to interviewer: a fall is defined as an 
event which results in a person coming to rest inadvertently on the ground or floor or other 
lower level)
Yes /
No /
Unknown
Q54 During the last 30 days, on how many of these days did you have a headache? 
(answer 0 if none)
________ /unknown
Page 26 of 36
https://mc.manuscriptcentral.com/esj
European Stroke Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Title: Studies of small vessel diseases: the Mild Stroke Study 3 (MSS-3). The 
longitudinal study of cerebral small vessel diseases following mild ischaemic stroke: 
rationale and design.
Supplement 2: 
(a) MRI protocol at baseline assessment
(b) Summary of image analysis methods
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(a) MRI protocol at baseline assessment
MRA Flow quantitative T1 DCE-
MRI
Sequence TOF 2D PC 
(carotids)
2D PC 
(SACSF)
2D PC 
(sinus)
3D IR-
sGRE (TI 
= 600 
ms)
3D IR-
sGRE (TI  
= 1500 
ms)
3D sGRE 
(FA = 2°,5°, 
12°)
T1w 3D 
sGRE
Voxel size 
(mm)
0.5x0.7x1.
6
1.0x1.0x5.0 0.8x0.8x5.0 0.7x0.7x5.
0
1.2x1.2x
1.2
1.2x1.2x1.
2
1.2x1.2x1.2 2x2x2
TR (ms) 20.0 19.60 25.18 21.70 1040 1940 5.4 3.44
TE (ms) 3.51 5.82 8.45 6.59 1.82 1.82 1.82 1.68
TI - - - - 600 1500 - -
Flip Angle 
(°)
20 12 12 12 5 5 2, 5, 12 15
Acquisition 
Time 
(mm:ss)
2:45 1:39 
approx.
1:55 approx. 2:11 
approx.
1:55 3:35 1:36 x 3 21:08
Other R=2
venc =
70 cm s-1
NA = 2
R=2
venc = 6 cm 
s-1
R=2
venc = 50 
cm s-1
R=2 R=2 R=2 32 
volumes
CVR T1w FLAIR PD T2w SWI dMRI ASL
Sequence 2D GE-
EPI
MPRAGE 
(3D IR-
sGRE)
SPACE 
(3D 
RARE)
3D sGRE SPACE 
(3D 
RARE)
3D 
sGRE
2D GE-EPI 3D 
pcASL
Voxel size 2.5x2.5x
2.5
1.0x1.0x1.
0
1.0x1.0x
1.0
1.0x1.0x
1.0
0.9x0.9x
0.9
0.6x0.
6x3.0
2.0x2.0x2.0 3.4x3.
5x3.5
TR 1550 2500 5000 6.04 3200 28 4300 4350
TE 30.0 4.37 388 2.44 408 20 74.0 20.98
TI - - 1100 1800 - - - -
Flip Angle 67 7 - 2.0 - 9 - -
Acquisition 
time
12:30 3:45 5:57 1:57 3:42 4.02 11:16 3:45
Other R=2, 
MB=2
R=3 R=3 R=3 R=2x2 R=2 R=2, MB=2
15 × b = 0 s/mm2, 3 × b 
= 200 s/mm2, 6 × b = 
R=2
TI = 
500-
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TI=1800 
ms
500 s/mm2, 64 × b = 
1000 s/mm2, 64 × b = 
2000 s/mm2
(3 x b0 acquired with 
reversed phase ecoding)
3030 
(x12)
CVR =Cerebrovascular reactivity; MPRAGE =Magnetization-prepared rapid acquisition with gradient 
echo; FLAIR =Fluid-attenuated inversion recovery; PD VIBE =Proton density; SPACE =Sampling 
perfection with application-optimized contrast using different flip-angle evolution; SWI 
=Susceptibility weighted imaging; dMRI =Diffusion imaging; pcASL =Pseudo-continuous arterial spin 
labelling; TOF =Time-of-flight; PC =Phase-contrast; SACSF =Subarachnoid cerebrospinal fluid; IR 
=Inversion recovery; sGRE =Spoiled gradient recalled echo; TI =Inversion time; FA =Flip angle; DCE 
=Dynamic contrast-enhanced; TR =Repetition time; TE =Echo time; R=parallel imaging acceleration 
factor; MB=multiband acceleration factor; NA = number of averages.
(b)  Summary of image analysis methods
Structural and Diffusion Imaging 
The index, old and recurrent infarcts and SVD imaging markers (i.e. white matter 
hyperintensities (WMH), lacunes, perivascular spaces (PVS) and microbleeds are assessed by 
an expert neuroradiologist using validated visual scores (1-4), and recorded in standard 
assessment templates (5, 6) as described previously.(7)
All images are converted from DICOM to NIFTI-1 format using dcm2niix 
(https://github.com/rordenlab/dcm2niix). For each patient, structural tissue/lesion 
segmentation is performed in the native space of the T2-weighted image acquired at visit 1. 
Therefore, we linearly align all structural sequences from all visits to this image space using 
FSL-FLIRT (8). The structural processing pipeline is fully automatic and combines the output 
from state-of-the-art neuroimaging processing tools: FSL-FAST (9), freesurfer 
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(https://surfer.nmr.mgh.harvard.edu/), LOTS-IM (10) and multispectral Gaussian clustering 
optimised using an Expectation-Maximisation algorithm (11) to output the volumes, 
probabilistic and binary masks of: 1) venous sinuses, meninges and main venous pathways, 
2) cerebrospinal fluid, 3) intense and less-intense WMH, 4) normal-appearing white matter 
5) deep grey matter structures, 6) cortical grey matter, 7) stroke lesions and 8) lacunes, total 
and per cerebral and cerebellar hemisphere. PVS are segmented in the native T2W space in 
the basal ganglia and centrum semiovale regions for each visit as described previously (2, 
12), both segmented fully automatically using the output from the main structural pipeline. 
Venous pathways and mineral deposition are segmented in the native SWI space using the 
minimum intensity projection, phase and magnitude images combined with the T1w 
sequence.(13, 14) 
Diffusion data are processed using TractoR version 3.3.(15) DICOM data are converted to 
NIfTI-1 format using ‘divest’ (16), corrected for susceptibility and eddy current induced 
distortions using topup and eddy from FSL version 6.0.1 (17-19), and the brain is masked 
using FSL’s brain extraction tool. The water self-diffusion tensor is calculated for each brain 
voxel, and parametric maps of fractional anisotropy (FA) and mean diffusivity (MD) are 
derived from its eigenvalues with TractoR’s ‘tensorfit' using an iterative weighted least-
squares approach.(20) NODDI parameters (intracellular volume fraction (ICVF), isotropic 
volume fraction (ISOVF) and orientation dispersion index (ODI)) will be determined from the 
registered multi-shell diffusion MRI data using the NODDI Matlab toolbox 
(http://mig.cs.ucl.ac.uk/).
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Advanced imaging measures of vessel function
Blood brain barrier permeability
Full details of the DCE-MRI acquisition protocol are available to download at the 
Harmonizing Brain Imaging Method for Vascular Contributions to Neurodegeneration 
(HARNESS) website (21): https://harness-neuroimaging.org 
In summary, we derive values for the blood plasma volume fraction (vP) and the capillary 
permeability-surface area product PS for each voxel and region as described in (22). 
Cerebrovascular flow, perfusion, and reactivity 
The multi-inversion time pseudo-continuous arterial spin labelling data is processed through 
FSL's BASIL using a 1-compartment model and partial volume correction to obtain cerebral 
blood flow and arterial transit time (12 equally spaced TIs=500-3030ms, 
TR/TE=4350/20.98ms with 4 background suppression pulses, bolus duration=1800ms).(23) 
Further analysis is performed using white and subcortical grey matter regions of interest.
We acquire four phase-contrast scans following manual placement of a 2D slice 
perpendicular to the following vessels before manual segmentation: internal carotid and 
vertebral arteries, internal jugular veins, venous sinuses (superior sagittal, straight, and 
transverse sinuses), subarachnoid CSF at the level of C2-C3 and aqueduct. We manually 
segment vessel regions of interest (ROIs) using FSLeyes before processing phase-contrast 
MRI data, using in-house MATLAB code to obtain flow measurements. 
We extract velocity on a pixel-by-pixel basis and calculate the blood/CSF flow for each 
vessel/space, performing aliasing and background corrections where required. We calculate  
flow across the cardiac cycle for each vessel and estimate the pulsatility index (PI = (max 
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flow - min flow) / mean flow). We also extract the pulse waveform delay between the 
carotids and other intracranial vessels.(24)
During the 12 minute cerebrovascular reactivity (CVR) paradigm using a Blood Oxygenation 
Level Dependent (BOLD) MRI, we record end-tidal CO2 (ETCO2) while participants 
alternately inhale medical air (2 minutes) and air containing 6% carbon dioxide (3 minutes). 
Linear regression with a variable CVR delay is used to extract measurements of 
cerebrovascular reactivity (% change in BOLD signal per mmHg change in ETCO2) and the 
delay value in white and grey matter.(25)
Retinal imaging
All retinal images are acquired with a SPECTRALIS imaging platform (Heidelberg Engineering, 
Heidelberg, Germany) that combines fundus imaging with a scanning laser ophthalmoscope 
and simultaneous optical coherence tomography (OCT) imaging. The camera employs 
spectral domain OCT which achieves micrometre resolution with very fast scanning times. 
The beam of a super luminescence diode scans across the retina to produce cross-sectional 
images, with an infrared wavelength of 870nm.
The retinal imaging protocol builds on systems successfully established during the Mild 
Stroke Study 1 at our centre.(26, 27) Both eyes are imaged during a 25minute protocol that 
includes: horizontal and vertical single line scans through the macula, enhanced depth 
imaging (EDI) to permit enhanced visualisation and subsequent measurement of the sub-
foveal choroidal thickness, posterior pole multi-line imaging that captures 61 individual 
slices inferiorly to superiorly across the retina, circular optic nerve head scan for vascular 
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assessment of main vessels and peripapillary retinal nerve fibre layer (RNFL) thickness 
measurements, and multicolour imaging via three colour wavelengths for an assessment of 
maculopathy and retinopathy. Additionally, we conduct optical coherence tomography 
angiography (OCTA) to assess the microvasculature, including vessel area density of the 
superficial vascular complex which supplies the RNFL and the ganglion cell layer.
The retinal images are used as input to two themes of analysis: vascular and neuroretinal. 
Fundus images are processed with the Vascular Assessment and Measurement Platform for 
Images of the REtina (VAMPIRE; Web version, Universities of Edinburgh and Dundee: 
vampire.computing.dundee.ac.uk), a validated software application for semi-automatic 
quantification of retinal vessel properties. RNFL segmentation is undertaken using the 
manufacturer’s software.  Vessel density of the small vessels discerned by OCTA is 
undertaken with bespoke image analysis software. We also administer a short ocular health 
questionnaire, assess visual acuity and measure eye axial length.
References
1. Fazekas F, Niederkorn K, Schmidt R, Offenbacher H, Horner S, Bertha G, et al. White matter 
signal abnormalities in normal individuals: correlation with carotid ultrasonography, cerebral blood 
flow measurements, and cerebrovascular risk factors. Stroke. 1988;19(10):1285-8.
2. Potter GM, Chappell FM, Morris Z, Wardlaw JM. Cerebral perivascular spaces visible on 
magnetic resonance imaging: development of a qualitative rating scale and its observer reliability. 
Cerebrovascular diseases (Basel, Switzerland). 2015;39(3-4):224-31.
3. Cordonnier C, Potter GM, Jackson CA, Doubal F, Keir S, Sudlow CL, et al. improving interrater 
agreement about brain microbleeds: development of the Brain Observer MicroBleed Scale (BOMBS). 
Stroke. 2009;40(1):94-9.
4. Penke L, Valdes Hernandez MC, Maniega SM, Gow AJ, Murray C, Starr JM, et al. Brain iron 
deposits are associated with general cognitive ability and cognitive aging. Neurobiology of aging. 
2012;33(3):510-7.e2.
5. Association between brain imaging signs, early and late outcomes, and response to 
intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): 
secondary analysis of a randomised controlled trial. The Lancet Neurology. 2015;14(5):485-96.
6. Wardlaw JM, Sellar R. A simple practical classification of cerebral infarcts on CT and its 
interobserver reliability. AJNR American journal of neuroradiology. 1994;15(10):1933-9.
7. Valdes Hernandez Mdel C, Armitage PA, Thrippleton MJ, Chappell F, Sandeman E, Munoz 
Maniega S, et al. Rationale, design and methodology of the image analysis protocol for studies of 
patients with cerebral small vessel disease and mild stroke. Brain and behavior. 2015;5(12):e00415.
Page 33 of 36
https://mc.manuscriptcentral.com/esj
European Stroke Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
8. Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and 
accurate linear registration and motion correction of brain images. NeuroImage. 2002;17(2):825-41.
9. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov 
random field model and the expectation-maximization algorithm. IEEE transactions on medical 
imaging. 2001;20(1):45-57.
10. Rachmadi MF, Valdes-Hernandez MDC, Li H, Guerrero R, Meijboom R, Wiseman S, et al. 
Limited One-time Sampling Irregularity Map (LOTS-IM) for Automatic Unsupervised Assessment of 
White Matter Hyperintensities and Multiple Sclerosis Lesions in Structural Brain Magnetic Resonance 
Images. Computerized medical imaging and graphics : the official journal of the Computerized 
Medical Imaging Society. 2019;79:101685.
11. McLachlan GJP, David. . Finite mixture models. New York ; Chichester :  Wiley. 2000.
12. Ballerini L, Lovreglio R, Valdes Hernandez MDC, Ramirez J, MacIntosh BJ, Black SE, et al. 
Perivascular Spaces Segmentation in Brain MRI Using Optimal 3D Filtering. Scientific reports. 
2018;8(1):2132.
13. A G. Characterisation and segmentation of basal ganglia mineralization in normal ageing 
with multimodal structural MRI. PhD Thesis. University of Edinburgh. . 2016.
14. Glatz A, Bastin ME, Kiker AJ, Deary IJ, Wardlaw JM, Valdes Hernandez MC. Automated 
segmentation of multifocal basal ganglia T2*-weighted MRI hypointensities. NeuroImage. 
2015;105:332-46.
15. Clayden JD MMS, Storkey AJ, King MD, Bastin ME, Clark CA. TractoR: Magnetic Resonance 
Imaging and Tractography with R. J Stat Softw 2011:44:1–18. Available at: http://www.tractor-
mri.org.uk/references.
16. Clayden JD RC. divest: Get images out of DICOM format quickly. 2017;Available at: 
https://cran.r-project.org/package=divest.
17. Andersson JL, Skare S, Ashburner J. How to correct susceptibility distortions in spin-echo 
echo-planar images: application to diffusion tensor imaging. NeuroImage. 2003;20(2):870-88.
18. Andersson JLR, Sotiropoulos SN. An integrated approach to correction for off-resonance 
effects and subject movement in diffusion MR imaging. NeuroImage. 2016;125:1063-78.
19. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, et al. 
Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage. 
2004;23 Suppl 1:S208-19.
20. Salvador R, Pena A, Menon DK, Carpenter TA, Pickard JD, Bullmore ET. Formal 
characterization and extension of the linearized diffusion tensor model. Hum Brain Mapp. 
2005;24(2):144-55.
21. Smith EE, Biessels GJ, De Guio F, de Leeuw FE, Duchesne S, During M, et al. Harmonizing 
brain magnetic resonance imaging methods for vascular contributions to neurodegeneration. 
Alzheimer's & dementia (Amsterdam, Netherlands). 2019;11:191-204.
22. Heye AK, Thrippleton MJ, Armitage PA, Valdes Hernandez MDC, Makin SD, Glatz A, et al. 
Tracer kinetic modelling for DCE-MRI quantification of subtle blood-brain barrier permeability. 
NeuroImage. 2016;125:446-55.
23. Chappell MA GA, Whitcher B, Woolrich MW. Variational Bayesian inference for a nonlinear 
forward model. IEEE Trans Signal Process. IEEE Trans Signal Process 2009;;57(1):223-236.
24. Shi Y, Thrippleton MJ, Blair GW, Dickie DA, Marshall I, Hamilton I, et al. Small vessel disease 
is associated with altered cerebrovascular pulsatility but not resting cerebral blood flow. Journal of 
cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood 
Flow and Metabolism. 2020;40(1):85-99.
25. Thrippleton MJ, Shi Y, Blair G, Hamilton I, Waiter G, Schwarzbauer C, et al. Cerebrovascular 
reactivity measurement in cerebral small vessel disease: Rationale and reproducibility of a protocol 
for MRI acquisition and image processing. International journal of stroke : official journal of the 
International Stroke Society. 2018;13(2):195-206.
Page 34 of 36
https://mc.manuscriptcentral.com/esj
European Stroke Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
26. Doubal FN, MacGillivray TJ, Hokke PE, Dhillon B, Dennis MS, Wardlaw JM. Differences in 
retinal vessels support a distinct vasculopathy causing lacunar stroke. Neurology. 2009;72(20):1773-
8.
27. Doubal FN, MacGillivray TJ, Patton N, Dhillon B, Dennis MS, Wardlaw JM. Fractal analysis of 
retinal vessels suggests that a distinct vasculopathy causes lacunar stroke. Neurology. 
2010;74(14):1102-7.
Page 35 of 36
https://mc.manuscriptcentral.com/esj
European Stroke Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Conflicting Interests
UC, MS, MJT, GB, AM, OH, CM, FND and JMW hold academic grants from government and 
charitable funding agencies, outlined below.
Funding
This work is supported by: the UK Dementia Research Institute which receives its funding 
from DRI Ltd, funded by the UK MRC, Alzheimer’s Society and Alzheimer’s Research UK; the 
Fondation Leducq Network for the Study of Perivascular Spaces in Small Vessel Disease (16 
CVD 05); Stroke Association ‘Small Vessel Disease-Spotlight on Symptoms (SVD-SOS)’ (SAPG 
19\100068; The Row Fogo Charitable Trust Centre for Research into Aging and the Brain; 
Stroke Association Garfield Weston Foundation Senior Clinical Lectureship (FND) (TSALECT 
2015/04); NHS Research Scotland (FND); Stroke Association Post-Doctoral Fellowship (SW) 
(SAPDF 18/100026); British Heart Foundation Edinburgh Centre for Research Excellence 
(RE/18/5/34216); NHS Lothian Research and Development Office (MJT); European Union 
Horizon 2020, PHC-03-15, project No666881, ‘SVDs@Target’ (MS,GB); Chief Scientist Office 
of Scotland Clinical Academic Fellowship (UC) (CAF/18/08); Stroke Association Princess 
Margaret Research Development Fellowship (UC) (2018); Medical Research Scotland 
studentship (AM) (PhD-1165-2017 ); College of Medicine and Veterinary Medicine, 
University of Edinburgh scholarship, as part of the Wellcome-funded Translational 
Neuroscience PhD programme (OH); MRC Doctoral Training Programme in Precision 
Medicine (CM) (MR/R01566X/1). The Research MR scanners are supported by the Scottish 
Funding Council through the Scottish Imaging Network, A Platform for Scientific Excellence 
(SINAPSE) Collaboration; the 3T scanner is funded by the Wellcome Trust (104916/Z/14/Z), 
Dunhill Trust (R380R/1114), Edinburgh and Lothians Health Foundation (2012/17), Muir 
Maxwell Research Fund, and the University of Edinburgh.
Approvals
Ethical approval for this study was obtained from South East Scotland Research Ethics 
Committee (Ref 18/SS/0044) on 31/05/2018. NHS Lothian Research & Development 
approved this study on 31/05/2018 (Ref 2018/0084)
Informed consent
Written informed consent is obtained from all subjects before the study
Trial registration
ISRCTN 12113543
Page 36 of 36
https://mc.manuscriptcentral.com/esj
European Stroke Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Guarantor
JMW
Authors' contributorship
UC: recruitment, data collection/management, study design, study coordination. DJG, WH: 
data collection/management, study coordination. IM, MB, MJT, MS, GB, SMM, ES, CM, 
AGM, IH: advanced neuroimaging techniques advice/design. TM, SW, KH, CH: retinal 
imaging techniques advice/design, data collection. MCVH, LB, MS, MJT: image analysis 
techniques advice/design. OH: cognitive test protocol advice, data collection. RB, EB: 
laboratory processing advice. DJ: data management. CA: advice regarding study design. FC: 
advice/study design, data management, statistical analysis plan. FD: recruitment, funding, 
study design, supervision, clinical oversight. JMW: conception, funding, ethics and 
regulatory approvals, study design, data collection, all supervision and governance, drafting 
and final editing of text. All authors also prepared, revised and approved the final 
manuscript.
Guarantor:  Prof Joanna Wardlaw  
Acknowledgements
We thank the participants, their families, radiographers at Edinburgh Imaging Facility Royal 
Infirmary of Edinburgh and the Stroke Research Network at the University of Edinburgh.
Page 37 of 36
https://mc.manuscriptcentral.com/esj
European Stroke Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
